Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nano Dimension Ltd - ADR — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Nano Dimension Ltd - ADR trades at $1.39 (market cap $306.41M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 3.2× Nano Dimension Ltd - ADR's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| MRVI | NNDM | |
|---|---|---|
Market Cap | $972.90M | $306.41M |
Volume | 4,325,710 | 1,735,346 |
Sector | Health | Technology |
52-Week High | $9.00 | $2.14 |
52-Week Low | $2.83 | $1.21 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $1.08B | -$98.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Nano Dimension (NNDM) trades at $1.41, down 6.62% with a bearish technical signal. The company shows revenue growth to $102.44M in 2025 but deepens net losses to -$293.30M, resulting in a negative net margin of -286.32%. Recent strategic moves include appointing a new board member and cost-saving initiatives targeting $25M in annual cash burn reduction. The stock faces significant selling pressure with 18 sell signals versus 7 buy signals in technical indicators.
The outlook remains challenging with persistent losses despite revenue growth. Investment opportunity exists in the company's cash position of $757.96M and low EV/EBITDA of 0.19, but risks include negative cash flow, leadership transitions, and shareholder activism. The stock trades near support levels with institutional sentiment cautious amid ongoing restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
